Trial reportJAMA psychiatry2025
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.
Trial report in JAMA psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05200936 (Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.International journal of molecular sciences · 2026Pooled it
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel, Switzerland) · 2026Review
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study.Psychopharmacology · 2026Article
- The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.Acta neuropsychiatrica · 2026Review
- U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.Rand health quarterly · 2026Article
- Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults.American journal of preventive medicine · 2026Article
- Psychedelic therapeutics in psychiatric conditions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics.Frontiers in neuroscience · 2026Article
- Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.Neuroscience applied · 2025Review
- What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.Therapeutic advances in psychopharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD's efficacy in reducing ADHD symptoms remains unknown. Objective: To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo. Design, Setting, and Participants: This was a 6-week, multicenter, double-blind, placebo-controlled, parallel-group phase 2A randomized clinical trial conducted between December 17, 2021, and December 4, 2023. Data were analyzed from March 22, 2024, to August 19, 2024. Outpatient treatment was provided at 2 centers: University Hospital in Basel, Switzerland, and Maastricht University in the Netherlands. Adults aged 18 to 65 years with a prior ADHD diagnosis who presented with moderate to severe symptoms (Adult Investigator Symptom Rating Scale [AISRS] score ≥26 and Clinical Global Impression Severity score ≥4) were eligible for inclusion. Key exclusion criteria included selected current major psychiatric or somatic disorders and the use of potentially interacting medications. Intervention: Participants received either LSD (20 μg) or placebo twice weekly for 6 weeks (total of 12 doses). Main Outcome and Measures: The primary outcome was the change in ADHD symptoms from baseline to week 6, assessed by the AISRS and analyzed with a mixed-effects model for repeated measures. Results: A total of 53 participants were randomized to LSD (n = 27) or placebo (n = 26). Mean (SD) participant age was 37 (12) years, and 22 participants (42%) were female. The LSD group presented a mean AISRS improvement of -7.1 points (95% CI, -10.1 to -4.0). The placebo group presented a mean AISRS improvement of -8.9 points (95% CI, -12.0 to -5.8), with no difference between groups. LSD was physically safe and psychologically well tolerated overall. Conclusions and Relevance: In this randomized clinical trial, repeated low-dose LSD administration was safe in an outpatient setting, but it was not more efficacious than placebo in reducing ADHD symptoms. Trial Registration: ClinicalTrials.gov Identifier: NCT05200936.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.